N2-[芴甲氧羰基]-N5-[苄氧羰基]-L-鸟氨酸 | 138775-07-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N2-[芴甲氧羰基]-N5-[苄氧羰基]-L-鸟氨酸
• 中文别名: 芴甲氧羰基-苄基-L-鸟氨酸
• 英文名称: Fmoc-Orn(Z)-OH
• 英文别名: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-5-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 138775-07-2
• 化学式: C₂₈H₂₈N₂O₆
• mdl: MFCD00190893
• 分子量: 488.54
• InChiKey: QRBAKCWBDLHBLR-VWLOTQADSA-N

物化性质

• 沸点：
  746.2±60.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  存储温度应保持在0°C。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-Orn(Z)-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-Orn(Z)-OH
CAS number: 138775-07-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C28H28N2O6
Molecular weight: 488.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N2-[芴甲氧羰基]-N5-[苄氧羰基]-L-鸟氨酸 在 palladium dihydroxide 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 二乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 57.0h， 生成 (2S,4R)-1-((2S,3R)-2-{(S)-5-Amino-2-[(4''-pentyloxy-[1,1';4',1'']terphenyl-4-carbonyl)-amino]-pentanoylamino}-3-tert-butoxy-butyryl)-4-tert-butoxy-pyrrolidine-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  环状氨基六肽的全合成和抗真菌评估。

  摘要：

  对治疗全身性真菌感染的新疗法的需求持续增长。天然存在的六肽棘皮菌素B（1）通过抑制β-1,3葡聚糖（一种重要的真菌细胞壁成分）的合成，显示出强大的抗真菌活性。尽管到目前为止，由于该试剂的理化特性而受到限制，但我们发现在“西北”位置带有氨基脯氨酸残基的类似物的合成可大大改善水溶性（> 5 mg / mL）。报道了基于整个细胞和一系列化合物的体内活性的合成和构效关系（SAR）。

  DOI：

  10.1016/s0968-0896(00)00097-3
• 作为产物：
  描述：

  N'-Cbz-L-鸟氨酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 N2-[芴甲氧羰基]-N5-[苄氧羰基]-L-鸟氨酸
  参考文献：
  名称：

  环状氨基六肽的全合成和抗真菌评估。

  摘要：

  对治疗全身性真菌感染的新疗法的需求持续增长。天然存在的六肽棘皮菌素B（1）通过抑制β-1,3葡聚糖（一种重要的真菌细胞壁成分）的合成，显示出强大的抗真菌活性。尽管到目前为止，由于该试剂的理化特性而受到限制，但我们发现在“西北”位置带有氨基脯氨酸残基的类似物的合成可大大改善水溶性（> 5 mg / mL）。报道了基于整个细胞和一系列化合物的体内活性的合成和构效关系（SAR）。

  DOI：

  10.1016/s0968-0896(00)00097-3

文献信息

• [EN] METHODS OF MODULATING THE ACTIVITY OF THE MC3 AND/OR MC4 RECEPTORS AND TREATMENT OF CONDITIONS RELATED TO THESE RECEPTORS<br/>[FR] PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DES RÉCEPTEURS MC3 ET/OU MC4 ET TRAITEMENT DES CONDITIONS ASSOCIÉES AUX DITS RÉCEPTEURS
  申请人：MIMETICA PTY LTD

  公开号：WO2010096854A1

  公开（公告）日：2010-09-02

  The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-3 receptor (MC3R) and / or the melanocortin-4 receptor (MC4R). Compounds of this invention can be used to treat diseases and/or conditions in which modulation of MC3R and / or MC4R is beneficial. Such diseases and/or conditions include, but are not limited to, obesity, eating disorders (such as cachexia, anorexia, weight gain, weight loss), metabolic syndrome, diabetes, sexual dysfunction (such as erectile dysfunction and female sexual dysfunction), anxiety, depression, inflammation, addiction and alcohol intake.

  本发明提供了一种化合物，其化学式为（I），可用于调节黑色素皮质素-3受体（MC3R）和/或黑色素皮质素-4受体（MC4R）的生物活性。本发明的化合物可用于治疗调节MC3R和/或MC4R有益的疾病和/或症状。这些疾病和/或症状包括但不限于肥胖、进食障碍（如虚弱、厌食、体重增加、体重减少）、代谢综合征、糖尿病、性功能障碍（如勃起功能障碍和女性性功能障碍）、焦虑、抑郁、炎症、成瘾和饮酒。
• CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1389460A1

  公开（公告）日：2004-02-18

  To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism. Nitrogen-containing compounds represented by the following general formula and CXCR4 antagonists containing these compounds as an active ingredient can be provided. The above compounds are typified by nitrogen-containing compounds represented by the following general formula (I) wherein A1 and A2 represent each a guanidino group or a group represented by the following general formula (ia) (wherein A3 represents a monocyclic or polycyclic heterocyclic aromatic ring group having 1 or 2 hetero atoms; B1 represents a single bond or alkylene group; and R1 represents hydrogen or alkyl group; W represents alkylene group having 2 to 3 carbon atoms, cyclic alkylene group having 5 to 10 carbon atoms, aromatic ring having 6 to 10 carbon atoms or heterocyclic aromatic ring having 5 to 10 carbon atoms; y is - (C=O) -; x is -C (=O) -NH-; n1 is an integer of 1 or 2; n2 is an integer of 2 or 3; and D is selected from among various substituents:

  为基于CXCR4拮抗作用提供对CXCR4具有拮抗作用的新型含氮化合物和治疗风湿病、癌症转移等疾病的药物。以下是一般式代表的含氮化合物和以这些化合物为活性成分的CXCR4拮抗剂。上述化合物以以下一般式（I）代表的含氮化合物为代表，其中A1和A2分别代表鸟氨基基团或由以下一般式（ia）代表的基团（其中A3代表具有1个或2个杂原子的单环或多环杂环芳香环基团；B1代表单键或烷基基团；R1代表氢或烷基基团；W代表具有2至3个碳原子的烷基基团、具有5至10个碳原子的环烷基团、具有6至10个碳原子的芳香环或具有5至10个碳原子的杂环芳香环；y为-(C=O)-；x为-C(=O)-NH-；n1为1或2的整数；n2为2或3的整数；D从各种取代基中选择）。
• Selection of DNA‐Encoded Dynamic Chemical Libraries for Direct Inhibitor Discovery
  作者：Yuqing Deng、Jianzhao Peng、Feng Xiong、Yinan Song、Yu Zhou、Jianfu Zhang、Fong Sang Lam、Chao Xie、Wenyin Shen、Yiran Huang、Ling Meng、Xiaoyu Li

  DOI：10.1002/anie.202005070

  日期：2020.8.24

  that can identify full ligand structures from large‐scale DEDLs. This method is also able to convert unbiased libraries into focused ones targeting specific protein classes. We demonstrated this method by selecting DEDLs against five proteins, and novel inhibitors were identified for all targets. Notably, several selective BD1/BD2 inhibitors were identified from the selections against bromodomain 4 (BRD4)

  动态组合库（DCL）是生物医学研究中配体发现的强大工具。但是，DCL的低多样性阻碍了它们的应用。最近，DCL中已经采用了DNA编码的概念来创建DNA编码的动态库（DEDL）。但是，当前所有的DEDL都仅限于片段识别，并且在选择后需要一个具有挑战性的片段链接过程。我们报告了一种锚定的DEDL方法，该方法可以从大规模DEDL中识别出完整的配体结构。这种方法还能够将无偏文库转换为针对特定蛋白质类别的集中文库。我们通过选择针对五种蛋白质的DEDLs证明了这种方法，并为所有靶标确定了新型抑制剂。值得注意的是 从针对重要的抗癌药物靶标bromodomain 4（BRD4）的选择中鉴定出了几种选择性的BD1 / BD2抑制剂。这项工作可以为抑制剂发现提供广泛适用的方法。
• Analogs of Deamino Carba Oxytocin with Inhibitory Properties; Synthesis and Biological Activities
  作者：Zdenko Procházka、Jiřina Slaninová、Tomislav Barth、Alena Stierandová、Jerzy Trojnar、Per Melin、Michal Lebl

  DOI：10.1135/cccc19921335

  日期：——

  Solid phase methodology on polyamide-kieselguhr resin was used for the synthesis of six analogs of deamino carba-1 or carba-6 oxytocin with non-coded amino acids in position 2, threonine in position 4, ornithine in position 8 and without glycine in position 9. The following analogs were prepared: des-Gly⁹-[L-Phe(p-Et)², Thr⁴, Orn⁸]deamino-carba-1-oxytocin (I), des-Gly⁹-[D-Phe(p-Et)², Thr⁴, Orn⁸]deamino-carba-1-oxytocin (II), des-Gly⁹-[D-Tyr(Et)², Thr⁴, Orn⁸]deamino-carba-1-oxytocin (III), des-Gly⁹-[L-Phe(p-Et)², Thr⁴, Orn⁸]deamino-carba-6-oxytocin (IV), des-Gly⁹-[D-Phe(p-Et)², Thr⁴, Orn⁸]deamino-carba-6-oxytocin (V), and des-Gly⁹-[D-Tyr(Et)², Thr⁴, Orn⁸]deamino-carba-1-oxytocin (VI). All the analogs were found to be strong uterotonic and pressor inhibitors. The highest potency in the uterotonic inhibitory test was exhibited by analog II (pA₂ = 8.3) and strongest pressor inhibitor was compound I (pA₂ = 7.5).

  使用聚酰胺-硅藻土树脂的固相方法合成了六种去氨基卡巴-1或卡巴-6催产素类似物，其中位置2为非编码氨基酸，位置4为苏氨酸，位置8为鸟氨酸，位置9没有甘氨酸。制备了以下类似物：去甘氨酸⁹-[L-Phe(p-Et)², Thr⁴, Orn⁸]去氨基卡巴-1-催产素（I），去甘氨酸⁹-[D-Phe(p-Et)², Thr⁴, Orn⁸]去氨基卡巴-1-催产素（II），去甘氨酸⁹-[D-Tyr(Et)², Thr⁴, Orn⁸]去氨基卡巴-1-催产素（III），去甘氨酸⁹-[L-Phe(p-Et)², Thr⁴, Orn⁸]去氨基卡巴-6-催产素（IV），去甘氨酸⁹-[D-Phe(p-Et)², Thr⁴, Orn⁸]去氨基卡巴-6-催产素（V），以及去甘氨酸⁹-[D-Tyr(Et)², Thr⁴, Orn⁸]去氨基卡巴-1-催产素（VI）。所有类似物均被发现具有强烈子宫收缩和升压抑制作用。在子宫收缩抑制测试中，类似物II表现出最高效力（pA₂ = 8.3），而最强的升压抑制剂是化合物I（pA₂ = 7.5）。
• Discovery of Diphenyloxazole and Nδ-Z-Ornithine Derivatives as Highly Potent and Selective Human Prostaglandin EP₄ Receptor Antagonists
  作者：Kouji Hattori、Akira Tanaka、Naoaki Fujii、Hisashi Takasugi、Yoshiyuki Tenda、Masayuki Tomita、Shoko Nakazato、Keiko Nakano、Yasuko Kato、Yutaka Kono、Hidetsugu Murai、Kazuo Sakane

  DOI：10.1021/jm050085k

  日期：2005.5.1

  Two novel classes of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective EP(4) antagonists have been discovered. The optimized diphenyloxzole 8 and Ndelta-Z-ornithine 11 effectively competed with [(3)H]PGE(2) binding to human recombinant EP(4), with K(i) values of 0.30 nM and 0.91 nM, respectively, and were selective for all members of the human prostanoid receptor family

  已发现两类新型的二苯基恶唑和Ndelta-Z-鸟氨酸衍生物作为高效和选择性的EP（4）拮抗剂。优化的二苯并恶唑8和Ndelta-Z-鸟氨酸11有效竞争与[（3）H] PGE（2）绑定到人类重组EP（4），K（i）值分别为0.30 nM和0.91 nM，分别为对人类前列腺素受体家族的所有成员具有选择性。8已显示在大鼠和狗中表现出良好的药代动力学特性，并且对体外PGE（2）促进的IgE合成具有强大的抑制活性。